Live feed13:30:00·510dPRReleasevia QuantisnowPfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder CancerByQuantisnow·Wall Street's wire, on your screen.PFE· Pfizer Inc.Health Care